Nonalcoholic fatty liver disease: Current and potential therapies
- 1 February 2013
- journal article
- review article
- Published by Elsevier BV in Life Sciences
- Vol. 92 (2), 114-118
- https://doi.org/10.1016/j.lfs.2012.11.004
Abstract
No abstract availableThis publication has 39 references indexed in Scilit:
- Lipid-Lowering Agents in Nonalcoholic Fatty Liver Disease and Steatohepatitis: Human StudiesDigestive Diseases and Sciences, 2012
- Mechanisms of Lipotoxicity in NAFLD and Clinical ImplicationsJournal of Pediatric Gastroenterology and Nutrition, 2011
- Betaine improved adipose tissue function in mice fed a high-fat diet: a mechanism for hepatoprotective effect of betaine in nonalcoholic fatty liver diseaseAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 2010
- Telmisartan attenuates progression of steatohepatitis in mice: role of hepatic macrophage infiltration and effects on adipose tissueLiver International, 2009
- Modulation of sterol regulatory element binding proteins (SREBPs) as potential treatments for non-alcoholic fatty liver disease (NAFLD)Drug Discovery Today, 2007
- Non‐alcoholic fatty liver disease: Further expression of the metabolic syndromeJournal of Gastroenterology and Hepatology, 2007
- Review: Non-alcoholic fatty liver disease: natural history, pathogenesis and treatmentBritish Journal of Diabetes, 2006
- Nonalcoholic Fatty Liver Disease: From Steatosis to CirrhosisHepatology, 2006
- NAFLD treatment: Cognitive-behavioral therapy has entered the arenaJournal of Hepatology, 2005
- Inhibition of Insulin Receptor Gene Expression and Insulin Signaling by Fatty Acid: Interplay of PKC Isoforms ThereinCellular Physiology and Biochemistry, 2005